Relationship of arachidonic acid release to porcine coronary artery relaxation

Hypertension. 1995 Oct;26(4):684-90. doi: 10.1161/01.hyp.26.4.684.

Abstract

In porcine coronary artery endothelium-dependent relaxation to bradykinin is in part attributed to a chemically unidentified factor, termed endothelium-derived hyperpolarizing factor (EDHF). We hypothesize that arachidonic acid, acting through a cyclooxygenase-independent mechanism, is responsible for EDHF production. To define the relationship between EDHF production and arachidonic acid release, we investigated the role of phospholipase C in bradykinin-induced relaxation and prostaglandin I2 production (an index of arachidonic acid release) in porcine coronary artery. The phospholipase C inhibitor U73122 (1 mumol/L) abolished bradykinin-induced, nitric oxide-mediated relaxation but did not inhibit either bradykinin-induced, EDHF-mediated relaxation or prostaglandin I2 production. However, when given at a larger dose (20 mumol/L) U73122 abolished both bradykinin-induced, EDHF-mediated relaxation and prostaglandin I2 production. Similarly, the calcium-ATPase inhibitor thapsigargin, given at a dose (1 mumol/L) that abolished bradykinin-induced increases in intracellular calcium concentration in cultured porcine coronary artery endothelial cells, eliminated both bradykinin-induced. EDHF-mediated relaxation and prostaglandin I2 production. Although thapsigargin abolished bradykinin-induced prostaglandin I2 production, the basal production of prostaglandin I2 was enhanced and contraction of endothelium-intact rings was attenuated. These latter responses are most likely related to enhanced basal arachidonic acid release and associated EDHF production. These observations suggest that phospholipase C activation and increased intracellular calcium concentration are required for both bradykinin-induced arachidonic acid release and EDHF production in porcine coronary artery.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Arachidonic Acid / physiology*
  • Arteries / physiology
  • Biological Factors / physiology
  • Bradykinin / pharmacology
  • Coronary Vessels / drug effects
  • Coronary Vessels / physiology*
  • Enzyme Inhibitors / pharmacology
  • Epoprostenol / biosynthesis
  • Estrenes / pharmacology
  • In Vitro Techniques
  • Pyrrolidinones / pharmacology
  • Swine
  • Terpenes / pharmacology
  • Thapsigargin
  • Type C Phospholipases / antagonists & inhibitors
  • Type C Phospholipases / physiology
  • Vasodilation / physiology*

Substances

  • Biological Factors
  • Enzyme Inhibitors
  • Estrenes
  • Pyrrolidinones
  • Terpenes
  • endothelium-dependent hyperpolarization factor
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • Arachidonic Acid
  • Thapsigargin
  • Epoprostenol
  • Type C Phospholipases
  • Bradykinin